IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene JUP Ensembl ENSG00000173801 Chromosome 17 Start 37164382 End 37196476
Description Junction plakoglobin (Desmoplakin-3)(Desmoplakin III)(Catenin gamma) [Source:UniProtKB/Swiss-Prot;Acc:P14923]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 6207
     Entrez Gene : 3728
     UCSC : uc002hxs.2
     GeneCards : 6207
     RefSeq : NM_002230
     CCDS : CCDS11407.1
     Uniprot : P14923
     Interpro : P14923
     OMIM : 173325
     GeneTests : JUP
     CGAP : JUP
     PMID : 1889810

< Top >


Somatic Mutaions        (help)
Lung cancer Adenocarcinoma Squamous Cell Carcinoma
Unique Mutated Samples % Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
Unique Mutated
Samples
% Mutated Total Unique
Samples
2 1.01 199 2 1.06 189 0 0.00 0
Sample datas
Sample Name Histology Subtype DNA Mutation Protein Mutation Mutation Description Zygosity Genomic Co-ordinates NCBI36 Pubmed
16835 AD c.607C>T p.R203C Substitution - Missense Heterozygous 17:37178847-3717884718948947
17759 AD c.712C>T p.P238S Substitution - Missense Heterozygous 17:37177354-3717735418948947

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  2047_s_at  0.59  1.77e-7  1.37e-6  1.49  1.89e-18  1.26e-16
 HG_U133A  201015_s_at  1.01  1.99e-29  2.98e-28  -1.64  5.17e-58  1.35e-57
 HG_U133_Plus2  201015_s_at  1.14  3.38e-15  4.68e-14  2.61  2.59e-33  1.78e-31
 Stanford  18199  0.35  3.40e-1  5.41e-1  0.99  1.50e-2  9.15e-2
 Agilent_HS_21.6K  2560  -0.04  3.17e-1  5.05e-1  -0.01  8.31e-1  8.96e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  201015_s_at  -0.15  5.75e-1  9.48e-1  0.15  5.38e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 2047_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 201015_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 201015_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 18199    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 2560    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
gamma-catenin non-small cell lung cancers The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3 cm or less in size. 11882822 Human
gamma-catenin tumor OBJECTIVES: Expression of the cell-cell adhesion molecules E-cadherin and alpha-, beta-, and gamma-catenin seems closely related to tumor invasiveness. 11882822 Human
gamma-catenin stage i non-small cell lung cancers CONCLUSION: Expression of alpha-, beta-, or gamma-catenin can be used as a prognostic indicator in patients with surgically resected stage I non-small cell lung cancers of 3 cm or less in size. 11882822 Human
gamma-catenin adenocarcinomas Tumor cell dedifferentiation correlated with reduced expression for E-cad, beta-catenin, gamma-catenin, and p120 in squamous cell carcinomas but not in adenocarcinomas. 12011119 Human
gamma-catenin tumor Tumor cell dedifferentiation correlated with reduced expression for E-cad, beta-catenin, gamma-catenin, and p120 in squamous cell carcinomas but not in adenocarcinomas. 12011119 Human
gamma-catenin squamous-cell carcinomas Tumor cell dedifferentiation correlated with reduced expression for E-cad, beta-catenin, gamma-catenin, and p120 in squamous cell carcinomas but not in adenocarcinomas. 12011119 Human
gamma-catenin metastasis There was an inverse correlation between nodal metastasis and expression of E-cad and gamma-catenin. 12011119 Human
gamma-catenin invasive breast cancer In this study, we have evaluated the expression of alpha-catenin but also of the other catenins (beta-, gamma- and p120-catenin) and E-cadherin in invasive breast cancer and statistically analysed these expressions with known clinicopathological parameter 12047765 Human
gamma-catenin endometrial carcinomas Loss of gamma-Catenin expression in squamous differentiation in endometrial carcinomas. 12068170 Human
gamma-catenin endometrial carcinomas In this study, we analyzed the immunohistochemical expression and localization of beta- and gamma-catenin, molecular changes in the beta-catenin gene, and the subcellular localization of the desmosomal component protein, desmoplakin, by laser scanning mic 12068170 Human
gamma-catenin endometrial carcinomas Our results suggest that unique molecular events, i.e., stimulation of beta-catenin and suppression of gamma-catenin expression, occur within endometrial carcinomas with squamous differentiation. 12068170 Human
gamma-catenin cancer E-cadherin and its associated cytoplasmic proteins including alpha-, beta-, and gamma-catenin play a pivotal role in the maintenance of normal tissue architecture and the suppression of cancer invasion. 12080224 Human
gamma-catenin early gastric cancer The purpose of this study was to evaluate the expression of E-cadherin and alpha-, beta-, and gamma-catenin in a larger sample of early gastric cancer, and to examine the relation between these expressions and various clinicopathologic variables. 12080224 Human
gamma-catenin early gastric cancer The expression of E-cadherin and alpha-, beta-, and gamma-catenin was investigated using immunohistochemical technique with formalin-fixed, paraffin-embedded tissue specimens obtained from 108 patients who underwent surgery for early gastric cancer. 12080224 Human
gamma-catenin cancer Reduced expression of E-cadherin and alpha-, beta-, and gamma-catenin was demonstrated in 43.5%, 39.8%, 42.6%, and 50% of cancer tissues, respectively. 12080224 Human
gamma-catenin cancer Reduced expression of E-cadherin and alpha- and gamma-catenin occurred more frequently in diffuse than in intestinal types of cancer, and decreased expression of E-cadherin and alpha-, beta-, and gamma-catenin correlated with poor differentiation. 12080224 Human
gamma-catenin lymph-node metastasis The expression of E-cadherin and beta- and gamma-catenin did not correlate with the patient's age, gender, tumor size, location, macroscopic type, depth of invasion, or lymph node metastasis. 12080224 Human
gamma-catenin tumor The expression of E-cadherin and beta- and gamma-catenin did not correlate with the patient's age, gender, tumor size, location, macroscopic type, depth of invasion, or lymph node metastasis. 12080224 Human
gamma-catenin tumours The APC protein interacts with beta-catenin and gamma-catenin and APC mutations are believed to play a role in the altered levels of beta-catenin in colorectal tumours. 12210065 Human
gamma-catenin human lung cancers gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. 12386812 Human
gamma-catenin tumors By contrast, gamma-catenin was weakly expressed or absent in several NSCLC cell lines and immunohistochemical analysis of primary NSCLC tumors revealed negligible to weak gamma-catenin staining in approximately 30% of the specimens. 12386812 Human
gamma-catenin cancers This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCF-dependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers. 12386812 Human
gamma-catenin tumor This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCF-dependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers. 12386812 Human
gamma-catenin endometrial carcinomas We investigated the expression pattern of beta- and gamma-catenin in a group of 128 endometrial carcinomas, including 95 endometrioid endometrial carcinomas (EECs) and 33 non-endometrioid endometrial carcinomas (NEECs). 12439748 Human
gamma-catenin endometrioid endometrial carcinomas We investigated the expression pattern of beta- and gamma-catenin in a group of 128 endometrial carcinomas, including 95 endometrioid endometrial carcinomas (EECs) and 33 non-endometrioid endometrial carcinomas (NEECs). 12439748 Human
gamma-catenin endometrial carcinoma Expression of E-cadherin and alpha-, beta-, gamma-catenin proteins in endometrial carcinoma. 12497652 Human
gamma-catenin lymph-node metastasis Aberrant expression of E-cadherin was correlated with lymph node metastasis and cell types other than endometrioid adenocarcinoma, while aberrant expression of gamma-catenin was related with deep myometrial invasion. 12497652 Human
gamma-catenin endometrioid adenocarcinoma Aberrant expression of E-cadherin was correlated with lymph node metastasis and cell types other than endometrioid adenocarcinoma, while aberrant expression of gamma-catenin was related with deep myometrial invasion. 12497652 Human
gamma-catenin prostate adenocarcinoma In conclusion, ATRA and CAT show anti-metastatic potential in the invasive rat prostate adenocarcinoma model and gamma-catenin appears to play a mechanistic role. 12553043 Human
gamma-catenin pituitary adenomas In this study, the expression of three major type I classic cadherins E-, N-, and P-cadherin and their undercoat proteins alpha-, beta-, and gamma-catenin, and pp120 was investigated in 127 pituitary adenomas and 10 normal adenohypophyseal glands using an 12665652 Human
gamma-catenin primary tumours RESULTS: There was under-expression in 85% of E-cadherin, 94% of alpha-catenin, 89% of beta-catenin, and 83% of gamma-catenin in the primary tumours. 11206273 Human
gamma-catenin metastasis Nodal metastasis was found in 68% of patients with weak expression of gamma-catenin compared with 9% with strong expression in primary tumours (chi-square, P = 0.02). 11206273 Human
gamma-catenin primary tumours Nodal metastasis was found in 68% of patients with weak expression of gamma-catenin compared with 9% with strong expression in primary tumours (chi-square, P = 0.02). 11206273 Human
gamma-catenin metastasis CONCLUSIONS: Both E-cadherin and catenins were highly under-expressed in oral tongue carcinoma, metastatic lymph node, and recurrent tumour. gamma-catenin had predictive value for nodal metastasis. 11206273 Human
gamma catenin squamous cell carcinoma of the oropharynx CONCLUSIONS: Reduced expression of gamma catenin is associated with dedifferentiation in primary squamous cell carcinoma of the oropharynx and hypopharynx. 11271788 Human
gamma-catenin colon carcinoma We found 1) significantly more gamma-catenin and SHP-2 bound to the truncated than to the full-length PECAM-1; 2) stable expression of the truncated PECAM-1 in SW480 colon carcinoma cells resulted in a dramatic decrease in cell proliferation, whereas expr 11156952 Human
gamma-catenin tumour Immunoblot study using affinity-purified gamma-catenin protein revealed that his serum recognized gamma-catenin (plakoglobin) in epidermal, thymic tumour and mouse bladder extracts. 11251577 Human
gamma-catenin non-small cell lung cancer Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. 11328840 Human
gamma-catenin tumour Reduced staining of alpha-catenin, beta-catenin, and gamma-catenin was related to poor differentiation of the tumour. 11328840 Human
gamma-catenin tumours The tumours with reduced staining of beta-catenin or gamma-catenin often had higher cell proliferation activity. 11328840 Human
gamma-catenin cervical cancer Expression and tyrosine phosphorylation of E-cadherin, beta- and gamma-catenin, and epidermal growth factor receptor in cervical cancer cells. 11371122 Human
gamma-catenin cervical cancer The present study aimed to confirm the hypothesis that EGF/epidermal growth factor receptor (EGFR) was related with the E-cadherin adhesion system in cervical cancer cells and that EGF might induce tyrosine phosphorylation of beta- and gamma-catenin. 11371122 Human
gamma-catenin cervical cancer CONCLUSIONS: EGF-induced scattering of the E-cadherin-positive cervical cancer cells might be the result of tyrosine phosphorylation of the beta- and gamma-catenin. 11371122 Human
gamma-catenin sarcomatoid renal cell carcinoma Cell proliferative activity and expression of cell-cell adhesion factors (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) in sarcomatoid renal cell carcinoma. 11398166 Human
gamma-catenin endometrial carcinoma Beta- and gamma-catenin expression in endometrial carcinoma. 11407474 Human
gamma-catenin endometrial carcinomas In this study, we investigate the immunohistochemical expression pattern (nuclear vs membranous) of beta- and gamma-catenin in 40 endometrial carcinomas and their correlation with clinicopathological features and microsatellite instability (MI) status. 11407474 Human
gamma-catenin carcinomas Nuclear catenin expression was found in 13 carcinomas: ten carcinomas had nuclear beta-catenin expression and three carcinomas had nuclear gamma-catenin expression. 11407474 Human
gamma-catenin tumor Abnormal immunoreactivity in the tumor tissue was observed in 18 patients (34.0%) for E-cadherin, in 35 (66.0%) for alpha-catenin, in 20 (37.7%) for beta-catenin, and in 37 (69.8%) for gamma-catenin. 11408802 Human
gamma-catenin tumors In diffuse-type tumors, abnormal expression of E-cadherin (60.9 vs. 13.3%, p < 0.0005), alpha-catenin (82.6 vs. 53.3%, p < 0.05) and gamma-catenin (91.3 vs. 53.3%, p < 0.005) was more frequent than in the intestinal type. 11408802 Human
gamma-catenin ovarian carcinomas Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. 11437403 Human
gamma-catenin small-cell lung carcinoma A missense mutation at codon 19 and a silent mutation at codon 28 in the NH2-terminal regulatory region of the gamma-catenin gene were found in H1726 (squamous cell lung carcinoma) and H1048 (small cell lung carcinoma), respectively. 11437403 Human
gamma-catenin squamous-cell lung carcinoma A missense mutation at codon 19 and a silent mutation at codon 28 in the NH2-terminal regulatory region of the gamma-catenin gene were found in H1726 (squamous cell lung carcinoma) and H1048 (small cell lung carcinoma), respectively. 11437403 Human
gamma-catenin human breast carcinomas The DF3/MUC1 transmembrane oncoprotein is aberrantly overexpressed in most human breast carcinomas and interacts with the Wnt effector gamma-catenin. 12939402 Human
gamma-catenin human breast carcinomas In concert with these results, we show nucleolar localization of MUC1 and gamma-catenin in human breast carcinomas but not in normal mammary ductal epithelium. 12939402 Human
gamma-catenin human colon adenocarcinomas Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. 14961975 Human
gamma-catenin benign tumors Immunohistochemical abnormalities in alpha-, beta-, and gamma-catenin have been reported in malignant and benign tumors, and nuclear localization of beta-catenin has been associated with mutations in exon 3 of this gene. 11579678 Human
gamma-catenin pituitary tumors We also analyzed immunohistochemical expression of alpha-, beta-, and gamma-catenin by paraffin sections from 154 pituitary tumors, including 148 adenomas and 6 carcinomas. 11579678 Human
gamma-catenin carcinomas We also analyzed immunohistochemical expression of alpha-, beta-, and gamma-catenin by paraffin sections from 154 pituitary tumors, including 148 adenomas and 6 carcinomas. 11579678 Human
gamma-catenin adenomas We also analyzed immunohistochemical expression of alpha-, beta-, and gamma-catenin by paraffin sections from 154 pituitary tumors, including 148 adenomas and 6 carcinomas. 11579678 Human
gamma-catenin tumors The lowest frequency immunopositive tumors and the weakest immunostaining was for gamma-catenin. 11579678 Human
gamma-catenin tumors All medically treated prolactinomas were negative for gamma-catenin, whereas treated growth hormone adenomas were less often positive for both alpha- and gamma-catenin than for untreated tumors. 11579678 Human
gamma-catenin adenomas All medically treated prolactinomas were negative for gamma-catenin, whereas treated growth hormone adenomas were less often positive for both alpha- and gamma-catenin than for untreated tumors. 11579678 Human
gamma-catenin carcinomas Most pituitary carcinomas were negative for both alpha- and gamma-catenin but were beta-catenin positive. 11579678 Human
gamma-catenin pituitary tumors These results indicate that (i) mutations in exon 3 of the beta-catenin gene are uncommon in pituitary tumors, and (ii) expression of alpha-, beta-, and gamma-catenin is decreased in pituitary adenomas compared to normal pituitary tissues. 11579678 Human
gamma-catenin pituitary adenomas These results indicate that (i) mutations in exon 3 of the beta-catenin gene are uncommon in pituitary tumors, and (ii) expression of alpha-, beta-, and gamma-catenin is decreased in pituitary adenomas compared to normal pituitary tissues. 11579678 Human
gamma-catenin murine bladder cancer Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer. 11585741 Human
gamma-catenin bladder cancer We hypothesize that beta- and gamma-catenin may play an important role in the pathogenesis of bladder cancer. 11585741 Mouse
gamma-catenin human bladder cancers We tested this hypothesis through analysis of beta- and gamma-catenin in both murine and human bladder cancers. 11585741 Human
gamma-catenin carcinoma Human bladder cancer specimens with normal tissues, dysplasia, carcinoma in situ, and carcinoma of grades, 1, 2, and 3 were also analyzed for beta- and gamma-catenin expression. beta- and gamma-catenin were analyzed for mutations by SSCP and direct DNA se 11585741 Human
gamma-catenin carcinoma in situ Human bladder cancer specimens with normal tissues, dysplasia, carcinoma in situ, and carcinoma of grades, 1, 2, and 3 were also analyzed for beta- and gamma-catenin expression. beta- and gamma-catenin were analyzed for mutations by SSCP and direct DNA se 11585741 Human
gamma-catenin human bladder cancer Human bladder cancer specimens with normal tissues, dysplasia, carcinoma in situ, and carcinoma of grades, 1, 2, and 3 were also analyzed for beta- and gamma-catenin expression. beta- and gamma-catenin were analyzed for mutations by SSCP and direct DNA se 11585741 Human
gamma-catenin invasive carcinoma Intracellular accumulation of beta- and gamma-catenin was observed in 6 of 20 invasive carcinoma specimens. 11585741 Mouse
gamma-catenin carcinoma in situ There was no intracellular accumulation of beta- and gamma-catenin in mucosal dysplasia, papillary or nodular dysplasia, and carcinoma in situ specimens. 11585741 Mouse
gamma-catenin invasive carcinomas On the other hand, SSCP analysis for gamma-catenin followed by sequencing revealed three mutations in two invasive carcinomas with intracellular accumulation of gamma-catenin. 11585741 Mouse
gamma-catenin human bladder cancer In human bladder cancer, beta- and gamma-catenin expression was significantly weaker than in normal bladder. 11585741 Mouse
gamma-catenin bladder cancer In summary, alterations in beta- and gamma-catenin are late events favoring tumor progression in mouse BBN-induced bladder cancer. 11585741 Mouse
gamma-catenin tumor In summary, alterations in beta- and gamma-catenin are late events favoring tumor progression in mouse BBN-induced bladder cancer. 11585741 Mouse
gamma-catenin cancer In human blabber cancer, beta- and gamma-catenin expression is similar to the expression in the mouse model. 11585741 Human
gamma-catenin bladder cancer The present study demonstrates that beta- and gamma-catenin may play an important role in bladder cancer progression. 11585741 Mouse
gamma-catenin keratoacanthoma The potential role of abnormal E-cadherin and alpha-, beta- and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma. 11703284 Human
gamma-catenin keratoacanthoma OBJECTIVES: To determine the pattern of E-cadherin and alpha-, beta- and gamma-catenin immunostaining in keratoacanthoma (KA) and to evaluate its potential value in routine histopathology in differentiating KA with benign from that with malignant biologic 11703284 Human
gamma-catenin sporadic colorectal carcinomas In this study, we compared the expression of E-cadherin and catenins (alpha-, beta-, and gamma-catenin) in 30 sporadic colorectal carcinomas with that in the adjacent nonneoplastic mucosa and assessed whether any perturbation in the level of expression oc 11727261 Human
gamma-catenin chondrosarcoma METHODS: By means of immunohistochemical techniques that incorporated a panel of monoclonal antibodies against cell adhesion molecules (CAMs), including E-cadherin, alpha-catenin, beta-catenin, gamma-catenin, and neural cell adhesion molecule (NCAM), the 11729215 Human
gamma-catenin chondrosarcoma In chondrosarcoma, only a few specimens showed positive immunoreactivity for CAMs and the expression of E-cadherin, beta-catenin, gamma-catenin, and NCAM was seen more frequently in the chordoma specimens than in the chondrosarcoma specimens. 11729215 Human
gamma-catenin pancreatic cancer Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. 11911306 Human
gamma-catenin pancreatic cancer MATERIALS AND METHODS: The immunohistochemical expression and cellular co-localization of alpha-, beta- and gamma-catenin were investigated in 43 paraffin-embedded specimens of pancreatic cancer. 11911306 Human
gamma-catenin metastases Both alpha-catenin and gamma-catenin expression correlated with disease stage and with lymph node and distant metastases, whereas aberrant beta-catenin expression only correlated with the presence of lymph node metastases. 11911306 Human
gamma-catenin lymph-node metastases Both alpha-catenin and gamma-catenin expression correlated with disease stage and with lymph node and distant metastases, whereas aberrant beta-catenin expression only correlated with the presence of lymph node metastases. 11911306 Human
gamma-catenin primary tumours These results demonstrate that tumour cells, when released from the primary site and after regrowth elsewhere, are capable of re-expression of adhesion molecules. gamma-catenin may play a different role in metastatic lesions than in primary tumours, since 10640987 Human
gamma-catenin tumour These results demonstrate that tumour cells, when released from the primary site and after regrowth elsewhere, are capable of re-expression of adhesion molecules. gamma-catenin may play a different role in metastatic lesions than in primary tumours, since 10640987 Human
jup tumours This was of interest since earlier studies have shown that JUP expression is altered in breast, lung and thyroid tumours as well as cell lines having LOH in chromosome 17q21. 15187990 Human
jup tumour However, no mutations were detected in JUP using single-strand conformation polymorphism analysis of primary breast tumour DNAs having LOH at 17q21. 15187990 Human
jup tumour We could find no evidence that the transcription promoter for JUP is methylated in tumour DNAs having LOH at 17q21. 15187990 Human
jup tumours We suspect that the target gene for LOH in primary human breast tumours on chromosome 17q21 is either JUP and results in a haploinsufficiency for expression or may be an unidentified gene located in the interval between D17S846 and JUP. 15187990 Human
gamma-catenin hepatocellular carcinoma Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. 10836294 Human
gamma-catenin tumor Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival. 10836294 Human
gamma-catenin hepatocellular carcinoma (hcc) We evaluated the immunohistochemical expression status of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin, and the relationship with tumor grade, clinicopathologic parameters, and patients' survival, in 107 surgically resected hepatocellul 10836294 Human
gamma-catenin tumor We evaluated the immunohistochemical expression status of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin, and the relationship with tumor grade, clinicopathologic parameters, and patients' survival, in 107 surgically resected hepatocellul 10836294 Human
gamma-catenin cancer Though beta- and gamma-catenin have analogous structures and functions and like binding to APC, evidence that gamma-catenin has an important role in cancer has been lacking. 10837025 Human
gamma-catenin colon cancer Our findings suggest APC mutations alter regulation of both beta- and gamma-catenin, perhaps explaining why the frequency of APC mutations in colon cancer far exceeds that of beta-catenin mutations. 10837025 Human
gamma-catenin cancers Elevated c-Myc expression in cancers with APC defects may be due to altered regulation of both beta- and gamma-catenin. 10837025 Human
gamma-catenin cancer Furthermore, the data imply beta- and gamma-catenin may have distinct roles in Wnt signaling and cancer via differential effects on downstream target genes. 10837025 Human
gamma-catenin human breast cancer In this study, we screened 24 human breast cancer cell lines and three immortalized human breast epithelial cell lines for alterations in beta- and gamma-catenin and APC by western blotting, protein truncation assay and DNA sequence analysis. 10874025 Human
gamma-catenin adenomatous polyposis coli Levels of the detergent-soluble pool of alpha- and gamma-catenin and the detergent-insoluble pool of the E-cadherin/catenin complex were unchanged by Taxol treatment and no significant difference was seen in the levels of adenomatous polyposis coli or gly 10996845 Human
gamma-catenin endometrioid adenocarcinomas To investigate the alterations in E-cadherin associated with cytoplasmic molecules including alpha-catenin, beta-catenin, gamma-catenin, p120CAS, and IQGAP1 in various endometrial cancers with different degree of differentiation, we examined the localizat 11027430 Human
gamma-catenin endometrial cancers To investigate the alterations in E-cadherin associated with cytoplasmic molecules including alpha-catenin, beta-catenin, gamma-catenin, p120CAS, and IQGAP1 in various endometrial cancers with different degree of differentiation, we examined the localizat 11027430 Human
gamma-catenin metastasis Finally, two cell lines obtained by ras transformation in vivo, and derived from a rat primary thyroid carcinoma (TK6) and its lung metastasis (MPTK6), were found to have lost gamma-catenin expression. 11043399 Rat
gamma-catenin thyroid carcinoma Finally, two cell lines obtained by ras transformation in vivo, and derived from a rat primary thyroid carcinoma (TK6) and its lung metastasis (MPTK6), were found to have lost gamma-catenin expression. 11043399 Mouse
gamma-catenin gastric cancer METHODOLOGY: The expression of E-cadherin, alpha-, beta-, and gamma-catenin, and p120 protein was evaluated by immunohistochemistry in 36 formalin-fixed, paraffin-embedded specimens of gastric cancer. 11100378 Human
gamma-catenin tumor The expression of E-cadherin and beta-catenin correlated significantly with the histological type and the degree of tumor differentiation. gamma-Catenin expression correlated only with the histological type of the tumor. 11100378 Human
gamma-catenin primary tumors Similar results were seen in the evaluation of primary tumors for gamma-catenin (P = 0.002). 11104606 Human
gamma-catenin ovarian carcinoma CONCLUSIONS: gamma-Catenin, and possibly c-erbB-2, are valid markers of poor survival in advanced-stage ovarian carcinoma. 11104606 Human
gamma-catenin tumours Abnormal immunoreactivity of beta- and gamma-catenin, including nuclear localization, was observed in 34% and 7.3% of tumours, respectively, but there was no significant correlation with tumour type or endoscopic appearance. 11113859 Human
gamma-catenin tumour Abnormal immunoreactivity of beta- and gamma-catenin, including nuclear localization, was observed in 34% and 7.3% of tumours, respectively, but there was no significant correlation with tumour type or endoscopic appearance. 11113859 Human
gamma-catenin ovarian carcinoma E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. 11113863 Human
gamma-catenin carcinoma Membrane immunoreactivity for E-cadherin and alpha-, beta-, and gamma-catenin was detected on carcinoma cells in the majority of the effusions, but rarely on reactive mesothelial cells (p<0.001 for all markers). 11113863 Human
gamma-catenin primary carcinomas As with effusions, metastatic lesions showed up-regulation of alpha-, beta-, and gamma-catenin when compared with primary carcinomas (p=0.002-0. 015). 11113863 Human
gamma-catenin tumor Age (>60 yr) and pTNM-stage were related to reduced alpha- and ss-catenin expression levels (P: = 0.027 and P: = 0.026, respectively) and larger size of the tumor to reduced ss- and gamma-catenin expressions (P: = 0.039 and P: = 0.007, respectively). 11134147 Human
gamma-catenin metastases Nodal metastases at the time of primary treatment related to reduced alpha-catenin expression and distal metastases to reduced ss- and gamma-catenin staining signals (P: = 0.022, P: = 0.014, and P: = 0.039, respectively). 11134147 Human
gamma-catenin gastric cancer Abnormal expression of E-cadherin and, alpha- and gamma-catenin occurred more frequently in diffuse than in intestinal type of gastric cancer, and correlated with poor differentiation. 11194192 Human
gamma-catenin prostatic carcinoma The expression of E-, N- and P-cadherin, alpha-, beta- and gamma-catenin, and actin was studied by immunohistochemistry, ELISA, and Western blot analysis in normal prostates, and in the prostates of men with benign prostatic hyperplasia and men with prost 11272805 Human
gamma-catenin benign prostatic hyperplasia The expression of E-, N- and P-cadherin, alpha-, beta- and gamma-catenin, and actin was studied by immunohistochemistry, ELISA, and Western blot analysis in normal prostates, and in the prostates of men with benign prostatic hyperplasia and men with prost 11272805 Human
gamma-catenin thyroid tumors In order to investigate the adhesion property of intercellular junctions in thyroid tumors, expression of alpha-,beta, and gamma-catenin should also be studied. 10595458 Human
gamma-catenin follicular adenoma In the normal thyroid and in nodular goiter, and follicular adenoma, staining for E-cadherin, alpha-, beta-, and gamma-catenin was seen mainly at the lateral surface of epithelial cells in the follicle and the presence of these molecules was confirmed by 10595458 Human
gamma-catenin follicular carcinomas Follicular carcinoma tissue stained positive for E-cadherin and alpha-catenin, but the results of beta- and gamma-catenin immunostaining were highly variable, with beta-catenin being absent in most follicular carcinomas (8/10) and gamma-catenin being abse 10595458 Human
gamma-catenin follicular carcinoma Follicular carcinoma tissue stained positive for E-cadherin and alpha-catenin, but the results of beta- and gamma-catenin immunostaining were highly variable, with beta-catenin being absent in most follicular carcinomas (8/10) and gamma-catenin being abse 10595458 Human
gamma catenin tumours Furthermore, membranous gamma catenin expression was not seen in any of the 70 melanocytic tumours studied, implying obligatory transmembrane binding of cadherins to beta catenin for maintenance of adhesive function. 10621837 Human
gamma-catenin oral squamous-cell carcinomas Beta- and gamma-catenin expression in oral squamous cell carcinomas. 10628318 Human
gamma-catenin squamous-cell carcinomas We evaluated by immunohistochemistry beta- and gamma-catenin expression in 30 cases of intraoral squamous cell carcinomas at different degree of cellular differentiation. 10628318 Human
gamma-catenin oral squamous-cell carcinomas As already reported for E-cadherin, the beta- and gamma-catenin expression showed an inverse relationship with the degree of differentiation, being the membranous expression of both catenins homogeneously reduced in less differentiated oral squamous cell 10628318 Human
gamma-catenin human lung cancer The reduced expression of e-cadherin, alpha-catenin and gamma-catenin but not beta-catenin in human lung cancer. 9864406 Human
gamma-catenin prostate cancers E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. 10206308 Human
gamma-catenin tumour E-cadherin and alpha-, beta- and gamma-catenin expression in prostate cancers: correlation with tumour invasion. 10206308 Human
gamma-catenin tumour In the present study, we examined E-cadherin and alpha-, beta- and gamma-catenin levels in tumour tissues obtained by radical prostatectomy in order to investigate the relationship with histopathological tumour invasion. 10206308 Human
gamma-catenin colorectal cancer Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. 10211089 Human
gamma-catenin adenocarcinoma Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. 15102950 Human
gamma-catenin cancer Our data suggest that proteolysis and altered localization of gamma-catenin are early markers for the response of cells to cisplatin, and reduced levels of gamma-catenin in resistant cells may indicate an important role for gamma-catenin in mediating or m 15102950 Human
gamma-catenin human colorectal cancer Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells. 11756231 Human
gamma-catenin tumour Abnormal expression of gamma-catenin was the sole predictor of high proliferation in NMST and was also correlated with the tumour grade, suggesting a possible important role for gamma-catenin in tumourigenesis. 11793366 Human
gamma-catenin cancer There is increasing experimental evidence to suggest that epidermal growth factor receptor tyrosine phosphorylation may lead to the inactivation of the E-cadherin/catenin complex in cancer cells through its interaction with beta- or gamma-catenin in the c 10365089 Human
gamma-catenin gastric carcinoma Expression of E-cadherin, alpha, beta and gamma-catenin and p120ctn, and of the adenomatous polyposis coli protein (APC), together with function of the cadherin-catenin complex was examined in a panel of gastric carcinoma cell lines, using immunocytochemi 10408833 Human
gamma-catenin pancreatic cancer Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. 10392898 Human
gamma-catenin endometrial cancer To further study the possible role of cell-to-cell interaction in growth regulation, we immunohistochemically analyzed 80 endometrial samples (30 of normal endometrium, 20 of endometrial hyperplasia, and 30 of endometrial cancer) for the expression of E-c 10411147 Human
gamma-catenin adenomatous polyposis coli (apc) To further study the possible role of cell-to-cell interaction in growth regulation, we immunohistochemically analyzed 80 endometrial samples (30 of normal endometrium, 20 of endometrial hyperplasia, and 30 of endometrial cancer) for the expression of E-c 10411147 Human
gamma-catenin endometrial hyperplasia To further study the possible role of cell-to-cell interaction in growth regulation, we immunohistochemically analyzed 80 endometrial samples (30 of normal endometrium, 20 of endometrial hyperplasia, and 30 of endometrial cancer) for the expression of E-c 10411147 Human
gamma-catenin melanocytic nevi In view of these studies, we have examined the expression of cytoplasmic proteins immunohistochemically in 13 melanocytic nevi, 34 primary cutaneous melanomas and 20 metastatic melanomas. alpha-, gamma-catenin and p120cas were heterogeneously expressed in 10503270 Human
gamma-catenin melanomas In view of these studies, we have examined the expression of cytoplasmic proteins immunohistochemically in 13 melanocytic nevi, 34 primary cutaneous melanomas and 20 metastatic melanomas. alpha-, gamma-catenin and p120cas were heterogeneously expressed in 10503270 Human
gamma-catenin melanocytic nevi These results indicated that alterations in alpha-, beta- and gamma-catenin and p120cas expression were common in melanocytic nevi and melanomas, and that loss of alpha-catenin expression was associated with melanoma invasiveness and metastasis. 10503270 Human
gamma-catenin metastasis These results indicated that alterations in alpha-, beta- and gamma-catenin and p120cas expression were common in melanocytic nevi and melanomas, and that loss of alpha-catenin expression was associated with melanoma invasiveness and metastasis. 10503270 Human
gamma-catenin melanoma These results indicated that alterations in alpha-, beta- and gamma-catenin and p120cas expression were common in melanocytic nevi and melanomas, and that loss of alpha-catenin expression was associated with melanoma invasiveness and metastasis. 10503270 Human
gamma-catenin melanomas These results indicated that alterations in alpha-, beta- and gamma-catenin and p120cas expression were common in melanocytic nevi and melanomas, and that loss of alpha-catenin expression was associated with melanoma invasiveness and metastasis. 10503270 Human
gamma-catenin anaplastic thyroid carcinoma The unequal expression of E-cadherin and gamma-catenin and the variable response to DNA de-methylation suggest that anaplastic thyroid carcinoma is not a uniform entity. 10521809 Human
gamma-catenin cancer This cell line should be of interest to those studying the role of the homologues, beta- and gamma-catenin, in cancer pathogenesis. 9563646 Human
gamma-catenin metastasis E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. 9771479 Human
gamma-catenin human breast carcinoma E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. 9771479 Human
gamma-catenin tumour Reduced or absent immunoreactivity in the tumour tissue was seen in 63 (70.0 per cent) for alpha-catenin, in 50 (55.6 per cent) for beta-catenin, and in 50 (55.6 per cent) for gamma-catenin. 9771479 Human
gamma-catenin metastases However, when all of the four proteins (E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin) were analysed as one group, a significant association was seen between reduction in immunoreactivity of at least one of these four proteins and the presenc 9771479 Human
gamma-catenin thyroid carcinomas Beta- and gamma-catenin expression in thyroid carcinomas. 9771480 Human
gamma-catenin human thyroid carcinomas The present study investigates the immunohistochemical expression of E-cadherin and beta- and gamma-catenin in 27 human thyroid carcinomas. 9771480 Human
gamma-catenin anaplastic carcinomas Gamma-catenin expression was partially or totally lost in 13/15 (86 per cent) papillary, 6/7 (85 per cent) follicular, and 5/5 (100 per cent) anaplastic carcinomas. 9771480 Human
gamma-catenin thyroid carcinomas The high frequency of alterations of gamma-catenin expression found in thyroid carcinomas suggests an important role for this gene product in thyroid carcinogenesis. 9771480 Human
gamma-catenin bladder cancer Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. 9783980 Human
gamma-catenin tumors Loss of normal surface E-cadherin, alpha-catenin, beta-catenin and gamma-catenin expression was found in 52/68 (76.4%) tumors, 57/68 (83.8%) tumors, 54/68 (79.4%) tumors and 54/68 (79.4%) tumors (p <0.001). 9783980 Human
gamma-catenin bronchioloalveolar carcinoma Expression of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study. 9831199 Human
gamma-catenin conventional pulmonary adenocarcinoma Expression of E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin in bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma: an immunohistochemical study. 9831199 Human
gamma-catenin adenocarcinomas We examined the expression of E-CD and alpha-, beta- and gamma-catenin immunohistochemically in 18 BACs (9 mucinous, 7 nonmucinous, and 2 sclerosing) in comparison with CPAs, all of which were well-differentiated adenocarcinomas. 9831199 Human
gamma catenin carcinoma in situ Immunohistochemical staining of squamous dysplasia/carcinoma in situ shows a striking increase in the proportion of cells within the epithelial compartment showing co-expression of E- and P-cad with strong appropriate membranous expression of beta and gam 9842964 Human
gamma-catenin oral squamous-cell carcinomas Double-label immunofluorescence has been used to stain a panel of 22 oral squamous cell carcinomas with antibodies to ten proteins, including E- and P-cadherin, the major keratinocyte integrin subunits, and alpha-, beta- and gamma-catenin. 9875134 Human
gamma-catenin tumor The aim of this study was to examine the expression of E-cadherin and alpha-, beta-, and gamma-catenin in gastric carcinoma and dysplasia and determine any relationship with tumor characteristics and survival. 8978342 Human
gamma-catenin gastric carcinoma The aim of this study was to examine the expression of E-cadherin and alpha-, beta-, and gamma-catenin in gastric carcinoma and dysplasia and determine any relationship with tumor characteristics and survival. 8978342 Human
gamma-catenin gastric carcinomas METHODS: Immunoperoxidase staining of E-cadherin and alpha-, beta-, and gamma-catenin was performed using 89 gastric carcinomas, lymph node metastases, and gastric biopsy specimens from 14 patients with dysplasia and 10 healthy controls. 8978342 Human
gamma-catenin lymph-node metastases METHODS: Immunoperoxidase staining of E-cadherin and alpha-, beta-, and gamma-catenin was performed using 89 gastric carcinomas, lymph node metastases, and gastric biopsy specimens from 14 patients with dysplasia and 10 healthy controls. 8978342 Human
gamma-catenin tumors Abnormal E-cadherin and gamma-catenin staining occurred more frequently in diffuse than intestinal tumors (P < 0.0005 and < 0.05, respectively). 8978342 Human
gamma-catenin mammary carcinomas 157 archival primary mammary carcinomas were immunohistochemically studied using antibodies against E-cadherin, alpha-, beta- and gamma-catenin. 9066580 Human
gamma-catenin human colorectal cancer Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. 9137497 Human
gamma-catenin colorectal cancer This study examined the expression of E-cadherin, alpha-, beta- and gamma-catenin in a series of colorectal cancer patients. 9137497 Human
gamma-catenin colonic polyps In this study, we have used immunohistochemistry to localize E-cadherin, alpha-, beta-, and gamma-catenin, and p120 in paraffin-embedded tissues from 60 patients with colonic polyps. 9176391 Human
gamma-catenin adenomas Decreased expression of the cadherin/catenin complex in adenomas was associated with increasing severity of dysplasia (p < 0.001, for E-cadherin, alpha-, and gamma-catenin, p < 0.005 for beta-catenin). 9216695 Human
gamma-catenin lobular breast carcinomas Expression patterns of E-cadherin and the molecules comprising the cytoplasmic complex of adherens junctions, alpha-, beta- and gamma-catenin, were studied in a series of 38 lobular breast carcinomas with known E-cadherin mutation status. 9496256 Human
gamma-catenin lobular carcinoma in situ These results indicate that simultaneous loss of E-cadherin and alpha-, beta- and gamma-catenin may be an important step in the formation of lobular carcinoma in situ, as a precursor of invasive lobular breast cancer. 9496256 Human
gamma-catenin lobular breast cancer These results indicate that simultaneous loss of E-cadherin and alpha-, beta- and gamma-catenin may be an important step in the formation of lobular carcinoma in situ, as a precursor of invasive lobular breast cancer. 9496256 Human
gamma-catenin tumors Regarding histopathological data, the tumors examined showed that the disrupted expression of each molecule, except for gamma-catenin, was directly related to increasing tumor grade (mainly for alpha- and beta-catenin) and deep invasion (p < or = 0.01). 9702939 Human
gamma-catenin tumor Regarding histopathological data, the tumors examined showed that the disrupted expression of each molecule, except for gamma-catenin, was directly related to increasing tumor grade (mainly for alpha- and beta-catenin) and deep invasion (p < or = 0.01). 9702939 Human
gamma-catenin tumor Because gamma-catenin is considered to be a tumor suppressor, our findings might give more insight into the tumor promoting actions of TCDD. 12478657 Human
gamma catenin tumours AIMS: To evaluate E-cadherin, beta catenin, gamma catenin, and ezrin expression and its relation to histopathological features of primary and metastatic Wilms's tumours. 12890743 Human
gamma catenin tumours METHODS: Immunohistochemistry was used to determine the expression and cellular distribution of E-cadherin, beta catenin, gamma catenin, and ezrin in primary and metastatic Wilms's tumours. 12890743 Human
gamma catenin metastatic tumours Low to high gamma catenin and ezrin expression was seen in cytoplasm of blastemal and epithelial cells of primary and metastatic tumours. 12890743 Human
gamma catenin metastatic tumours CONCLUSIONS: Compared with primary tumours, metastatic tumours showed lower expression of E-cadherin and gamma catenin, with nuclear staining for beta catenin. 12890743 Human
gamma catenin primary tumours CONCLUSIONS: Compared with primary tumours, metastatic tumours showed lower expression of E-cadherin and gamma catenin, with nuclear staining for beta catenin. 12890743 Human
gamma-catenin cutaneous squamous cell carcinomas RESULTS: Immunohistochemical reactivity (number positive/number of cases tested [percent positive], frequency of staining) included keratin 14 (31/64 [48%], variable), gamma-catenin (35/74 [47%], variable), keratin 5/6 (10/33 [30%], focal), calretinin (8/ 12946229 Human
gamma-catenin anaplastic carcinomas Gamma-catenin mRNA was decreased in anaplastic carcinomas compared with normal/follicular adenoma groups. 12605035 Human
gamma-catenin follicular adenoma Gamma-catenin mRNA was decreased in anaplastic carcinomas compared with normal/follicular adenoma groups. 12605035 Human
gamma-catenin papillary and follicular carcinomas A similar expression profile of gamma-catenin as beta-catenin was observed in papillary and follicular carcinomas with the latter once again having higher mRNA levels. 12605035 Human
gamma-catenin thyroid cancer These results therefore suggest that although beta- and gamma-catenin may play a role in the progression of thyroid cancer in general, they do not appear to be associated with ret/PTC-1-modulated pathways. 12605035 Human
gamma-catenin endometrial cancer Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. 12635138 Human
gamma-catenin atypical hyperplasia Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. 12635138 Human
gamma-catenin infiltrating lobular breast carcinomas (ilcs) To test this hypothesis, we have analyzed the presence of genetic and epigenetic alterations affecting E-CD (CDH1), APC and beta-catenin (CTNNB1) genes and the immunohistochemical expression of E-CD, beta- and gamma-catenin in a series of 46 infiltrating 12800196 Human
gamma-catenin tumors However, beta- and gamma-catenin were severely reduced or absent in 90% of these tumors, implying that alterations in CDH1 and APC genes do not promote beta-catenin accumulation in ILC. 12800196 Human
gamma-catenin gallbladder carcinomas We investigated the expression of 10 adhesion molecules (alpha-catenin, beta-catenin, gamma-catenin, CD44, CD44v6, ICAM-1, CD56, CEA, E-cadherin, and CD99) in 46 gallbladder carcinomas, 14 adenomas, 15 low-grade dysplasias, nine intestinal metaplasias, an 15100237 Human
gamma-catenin adenomas We investigated the expression of 10 adhesion molecules (alpha-catenin, beta-catenin, gamma-catenin, CD44, CD44v6, ICAM-1, CD56, CEA, E-cadherin, and CD99) in 46 gallbladder carcinomas, 14 adenomas, 15 low-grade dysplasias, nine intestinal metaplasias, an 15100237 Human
gamma-catenin metaplasias We investigated the expression of 10 adhesion molecules (alpha-catenin, beta-catenin, gamma-catenin, CD44, CD44v6, ICAM-1, CD56, CEA, E-cadherin, and CD99) in 46 gallbladder carcinomas, 14 adenomas, 15 low-grade dysplasias, nine intestinal metaplasias, an 15100237 Human
junction plakoglobin seminomas On the list were cyclin D2 (CCND2), prostate cancer over-expressed gene 1 (POV1), and junction plakoglobin (JUP), all of which were already known to be over-expressed in seminomas. 14612934 Human
jup seminomas On the list were cyclin D2 (CCND2), prostate cancer over-expressed gene 1 (POV1), and junction plakoglobin (JUP), all of which were already known to be over-expressed in seminomas. 14612934 Human
jup thyroid tumours This was of interest since earlier studies have shown that JUP expression is altered in breast, lung and thyroid tumours as well as cell lines having LOH in chromosome 17q21. 15187990 Human
jup breast tumour However, no mutations were detected in JUP using single-strand conformation polymorphism analysis of primary breast tumour DNAs having LOH at 17q21. 15187990 Human
jup breast tumours We suspect that the target gene for LOH in primary human breast tumours on chromosome 17q21 is either JUP and results in a haploinsufficiency for expression or may be an unidentified gene located in the interval between D17S846 and JUP. 15187990 Human
jup tumors At the protein level, expression of the immunohistochemical markers cytokeratins (pan-cytokeratin staining), placental-like alkaline phosphatase, anti-cytokeratin clone 5.2, CD30, anion exchanger 1/3, junction plakoglobulin (JUP), and POU domain, class 5, 16115909 Human
jup seminomas At the protein level, expression of the immunohistochemical markers cytokeratins (pan-cytokeratin staining), placental-like alkaline phosphatase, anti-cytokeratin clone 5.2, CD30, anion exchanger 1/3, junction plakoglobulin (JUP), and POU domain, class 5, 16115909 Human
gamma-catenin intestinal tumors Abnormal E-cadherin and gamma-catenin staining occurred more frequently in diffuse than intestinal tumors (P < 0.0005 and < 0.05, respectively). 8978342 Human
gamma-catenin epithelial tumor Expression of beta-catenin and gamma-catenin in epithelial tumor cell lines and characterization of a unique cell line. 9563646 Human
gamma-catenin epithelial tumor Twenty-five epithelial tumor cell lines were screened; 18 expressed both beta- and gamma-catenin, two expressed neither protein, four showed beta- but not gamma-catenin expression, while only one cell line showed gamma- but not beta-catenin expression. 9563646 Human
gamma-catenin crohn's disease The expression of E-cadherin; alpha-, beta-, and gamma-catenin; and p120 was evaluated immunohistochemically in 31 paraffin-embedded colonic specimens from 21 patients with ulcerative colitis and Crohn's disease. 9828841 Human
gamma-catenin crohn's disease There were no changes in beta- and gamma-catenin expression in either ulcerative colitis on Crohn's disease. 9828841 Human
gamma-catenin hcc Kaplan-Meier examination of patients' survival indicated that HCC patients with underexpression of E-cadherin, alpha-catenin, and gamma-catenin, and patients with overexpression of beta-catenin, had poor survival rates. 10836294 Human
gamma-catenin hcc These results suggest that E-cadherin is downregulated while the 3 catenins are upregulated in HCC, that E-cadherin expression inversely correlates with HCC grade while the 3 catenins' expression positively correlates with HCC grade, and that HCC pat 10836294 Human
gamma-catenin hyperplastic E-, N- and P-cadherin, and alpha-, beta- and gamma-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. 11272805 Human
gamma-catenin hyperplastic Hyperplastic prostates differ form normal prostates in the weaker immunoreaction to the three cadherin types, the two catenins, and actin, as well as in the intracellular distribution of P-cadherin, beta- and gamma-catenin, and actin. 11272805 Human
gamma-catenin thymic tumour Immunoblot study using affinity-purified gamma-catenin protein revealed that his serum recognized gamma-catenin (plakoglobin) in epidermal, thymic tumour and mouse bladder extracts. 11251577 Human
gamma-catenin nsclc CONCLUSIONS: The expression of alpha-catenin, beta-catenin, and gamma-catenin is related to histological type and differentiation in NSCLC, although catenins have no independent prognostic value. 11328840 Human
gamma-catenin pituitary carcinomas Most pituitary carcinomas were negative for both alpha- and gamma-catenin but were beta-catenin positive. 11579678 Human
gamma-catenin neoplasia BACKGROUND: Failure of E-cadherin and its associated proteins alpha-, beta- and gamma-catenin is believed to lead to disruption of cell-cell adhesion and to contribute to neoplasia. 11703284 Human
gamma-catenin colorectal tumours The APC protein interacts with beta-catenin and gamma-catenin and APC mutations are believed to play a role in the altered levels of beta-catenin in colorectal tumours. 12210065 Human
gamma-catenin nsclc By contrast, gamma-catenin was weakly expressed or absent in several NSCLC cell lines and immunohistochemical analysis of primary NSCLC tumors revealed negligible to weak gamma-catenin staining in approximately 30% of the specimens. 12386812 Human
gamma-catenin nsclc Treatment of NSCLC cells expressing reduced gamma-catenin protein with 5-aza-2'-deoxycytidine (5aza2dc), a DNA methylation inhibitor, or trichostatin A (TSA), a histone deacetylase inhibitor, increased gamma-catenin protein content in NSCLC cells wit 12386812 Human
gamma-catenin nsclc Significantly, the activity of a beta-catenin/TCF-dependent luciferase reporter was markedly elevated in the NSCLC cell lines that underexpressed gamma-catenin relative to those lines that highly expressed gamma-catenin. 12386812 Human
gamma-catenin nsclc This study shows that gamma-catenin can function as an inhibitor of beta-catenin/TCF-dependent gene transcription and highlights gamma-catenin as a potentially novel tumor suppressor protein in a subset of human NSCLC cancers. 12386812 Human
gamma-catenin metastasis [Relationship between the expression of E-cadherin-catenins and alpha-, beta-, gamma-catenin and the metastasis and prognosis of breast cancer] OBJECTIVE: To investigate the relationship between E-cadherin, alpha-, beta-, gamma-catenin expression and clin 12658921 Human
gamma-catenin breast cancer [Relationship between the expression of E-cadherin-catenins and alpha-, beta-, gamma-catenin and the metastasis and prognosis of breast cancer] OBJECTIVE: To investigate the relationship between E-cadherin, alpha-, beta-, gamma-catenin expression and clin 12658921 Human
gamma-catenin breast cancer METHODS: The expression of E-cadherin and alpha-, beta-, gamma-catenin in 40 breast cancer specimens was studied by the immunohistochemical method. 12658921 Human
gamma-catenin breast cancer However, when all the four proteins (E-cadherin, alpha-, beta-, gamma-catenin) were analyzed as one group, a significant association was found between the abnormal expression of two or more of these four proteins and the metastasis and prognosis of breast 12658921 Human
gamma-catenin metastasis However, when all the four proteins (E-cadherin, alpha-, beta-, gamma-catenin) were analyzed as one group, a significant association was found between the abnormal expression of two or more of these four proteins and the metastasis and prognosis of breast 12658921 Human
gamma-catenin breast cancer Moreover, when all the four proteins (E-cadherin, alpha-, beta-, gamma-catenin) are considered together, the accuracy and sensitivity predicting metastasis and prognosis of breast cancer could be increased. 12658921 Human
gamma-catenin metastasis Moreover, when all the four proteins (E-cadherin, alpha-, beta-, gamma-catenin) are considered together, the accuracy and sensitivity predicting metastasis and prognosis of breast cancer could be increased. 12658921 Human
gamma-catenin ca The objective of this study was to examine the expression of E-cadherin's ligands, beta- and gamma-catenin, in various thyroid tissue types in the context of ret/PTC-1 positivity using laser capture microdissection and TaqMan (Applied Biosystems, Fos 12605035 Human
gamma-catenin gastric carcinoma [Correlation of E-cadherin, beta-catenin and gamma-catenin gene expression with the invasion and metastasis of gastric carcinoma] OBJECTIVE: To study the association of the expressions of E-cadherin, beta;- and gamma-catenins in gastric carcinoma tissues 14625188 Human
gamma-catenin metastasis [Correlation of E-cadherin, beta-catenin and gamma-catenin gene expression with the invasion and metastasis of gastric carcinoma] OBJECTIVE: To study the association of the expressions of E-cadherin, beta;- and gamma-catenins in gastric carcinoma tissues 14625188 Human
gamma-catenin metaplasia METHODS: From 60 patients with gastric carcinoma, the paraffin-embedded specimens including 60 carcinoma tissues, 20 precancerous lesions (10 intestinal metaplasia and 10 dysplasia specimens) and 20 corresponding normal tissues adjacent to the carcinomas 14625188 Human
gamma-catenin carcinomas METHODS: From 60 patients with gastric carcinoma, the paraffin-embedded specimens including 60 carcinoma tissues, 20 precancerous lesions (10 intestinal metaplasia and 10 dysplasia specimens) and 20 corresponding normal tissues adjacent to the carcinomas 14625188 Human
gamma-catenin gastric carcinoma METHODS: From 60 patients with gastric carcinoma, the paraffin-embedded specimens including 60 carcinoma tissues, 20 precancerous lesions (10 intestinal metaplasia and 10 dysplasia specimens) and 20 corresponding normal tissues adjacent to the carcinomas 14625188 Human
gamma-catenin carcinoma METHODS: From 60 patients with gastric carcinoma, the paraffin-embedded specimens including 60 carcinoma tissues, 20 precancerous lesions (10 intestinal metaplasia and 10 dysplasia specimens) and 20 corresponding normal tissues adjacent to the carcinomas 14625188 Human
gamma-catenin dermal nevi METHODS: Immunohistochemical analysis of the expression of E-, P-, and N-cadherin and alpha-, beta-, and gamma-catenin in compound and dermal nevi, Spitz nevi, blue nevi, ultraviolet B (UVB)-irradiated nevi, and malignant melanomas of various tumor thickn 14675278 Human
gamma-catenin blue nevi METHODS: Immunohistochemical analysis of the expression of E-, P-, and N-cadherin and alpha-, beta-, and gamma-catenin in compound and dermal nevi, Spitz nevi, blue nevi, ultraviolet B (UVB)-irradiated nevi, and malignant melanomas of various tumor thickn 14675278 Human
gamma-catenin tumor METHODS: Immunohistochemical analysis of the expression of E-, P-, and N-cadherin and alpha-, beta-, and gamma-catenin in compound and dermal nevi, Spitz nevi, blue nevi, ultraviolet B (UVB)-irradiated nevi, and malignant melanomas of various tumor thickn 14675278 Human
gamma-catenin malignant melanomas METHODS: Immunohistochemical analysis of the expression of E-, P-, and N-cadherin and alpha-, beta-, and gamma-catenin in compound and dermal nevi, Spitz nevi, blue nevi, ultraviolet B (UVB)-irradiated nevi, and malignant melanomas of various tumor thickn 14675278 Human
gamma-catenin non-small cell lung cancers Gamma-catenin expression is reduced or absent in a subset of human non-small cell lung cancers, and its re-expression inhibits cell growth. 15136458 Human
gamma-catenin malignant mesothelioma Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. 15261432 Human
gamma-catenin tumours RESULTS: Immunohistochemistry demonstrated redistribution of E-cadherin, alpha-, beta- and gamma-catenin from the membrane to the cytoplasm in 13/24 (54%), 18/24 (75%), 16/24 (67%) and 15/24 (63%) tumours, respectively. 15274297 Human
gamma-catenin adenomas Our recent immunohistochemical study showed that expression of E-cadherin and its undercoat proteins, alpha-, beta- and gamma-catenin, in GH cell adenomas with prominent fibrous bodies was significantly reduced compared with GH cell adenomas without fibro 15281343 Human
gamma-catenin squamous cervical carcinoma (scc) OBJECTIVES: To examine the prognostic significance of the protein expression of E-cadherin, alpha-, beta-, and gamma-catenin in early squamous cervical carcinoma (SCC). 15297198 Human
gamma-catenin tumors RESULTS: Membrane expression for E-cadherin, alpha-, beta-, and gamma-catenin was decreased and low expression (< or =50% positive cells) was found in 198/219 (90%), 154/219 (70%), 157/219 (72%), and 181/219 (83%) tumors, respectively, and high (>50% posi 15297198 Human
gamma-catenin renal-cell carcinomas PATIENTS AND METHODS: One hundred and twenty-four renal cell carcinomas were prospectively followed-up for a mean of 3.5 years and the survival data of patients were related to standard prognostic factors and to the results of alpha-, beta- and gamma-cate 15330191 Human
gamma-catenin invasive lobular carcinoma (ilc) [E-cadherin associated protein expression and its significance in invasive lobular carcinoma and invasive ductal carcinoma of breast] OBJECTIVE: To study E-cadherin associated proteins alpha-, beta-, gamma-catenin expression and their significance in inva 11866953 Human
gamma-catenin invasive ductal carcinoma (idc) [E-cadherin associated protein expression and its significance in invasive lobular carcinoma and invasive ductal carcinoma of breast] OBJECTIVE: To study E-cadherin associated proteins alpha-, beta-, gamma-catenin expression and their significance in inva 11866953 Human
gamma-catenin invasive breast carcinoma METHODS: Immunohistochemistry staining (labeled streptavidin-biotin method) was used to detect alpha-, beta-, gamma-catenin expression in invasive breast carcinoma (19 cases of ILC and 32 cases of IDC ). 11866953 Human
gamma-catenin invasive carcinoma of breast The staining intensity of alpha-, beta-, gamma-catenin expression in invasive carcinoma of breast was weaker than that in foci of carcinoma in situ (semiquantitative grading). 11866953 Human
gamma-catenin carcinoma in situ The staining intensity of alpha-, beta-, gamma-catenin expression in invasive carcinoma of breast was weaker than that in foci of carcinoma in situ (semiquantitative grading). 11866953 Human
gamma-catenin lymph-node metastasis No significant association was seen between reduced protein expression of alpha-, beta-, gamma-catenin and the development of lymph node metastasis. 11866953 Human
gamma-catenin invasive breast carcinoma CONCLUSION: alpha-, beta-, gamma-catenin expression was almost identical in ILC and IDC of breast, showing significant loss and reduction of protein expression in the carcinoma cells of invasive breast carcinoma, suggesting that alpha-, beta-, gamma-caten 11866953 Human
gamma-catenin carcinoma CONCLUSION: alpha-, beta-, gamma-catenin expression was almost identical in ILC and IDC of breast, showing significant loss and reduction of protein expression in the carcinoma cells of invasive breast carcinoma, suggesting that alpha-, beta-, gamma-caten 11866953 Human
gamma-catenin primary ovarian carcinoma In this study, we investigated the clinical relevance of alpha-, beta-, and gamma-catenin immunoexpression in 104 cases of primary ovarian carcinoma with respect to clinicopathological features and as predictors of disease recurrence and prognosis. 15381903 Human
gamma-catenin human colon carcinoma [Change in E-cadherin, alpha-, beta- and gamma-catenin expression after hyperthermia of a human colon carcinoma cell line in vitro] OBJECTIVE: To investigate changes in E-cadherin, alpha-, beta-, and gamma-catenin expression after hyperthermia of a human 15387970 Human
gamma-catenin human colon cancer [Change in E-cadherin, alpha-, beta- and gamma-catenin expression after hyperthermia of a human colon carcinoma cell line in vitro] OBJECTIVE: To investigate changes in E-cadherin, alpha-, beta-, and gamma-catenin expression after hyperthermia of a human 15387970 Human
gamma-catenin human colon carcinoma METHODS: E-cadherin and alpha-, beta-, and gamma-catenin expression on a human colon carcinoma cell line HT29 at 7 successive times after hyperthermia at 43 degrees C for 60 min were investigated in vitro by RT-PCR and immunochemistry. 15387970 Human
gamma-catenin colon carcinoma CONCLUSION: Hyperthermia at 43C for 60 min upregulated E-cadherin and gamma-catenin expressions but downregulated beta-catenin expression on colon carcinoma cells in vitro. alpha-catenin expression was not regulated by hyperthermia. 15387970 Human
gamma-catenin esophageal squamous-cell carcinoma Prognostic and clinicopathological features of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D1 expression in human esophageal squamous cell carcinoma. 15484291 Human
gamma-catenin esophageal squamous-cell carcinoma (escc) AIM: To investigate the expression of E-cadherin, alpha-catenin, beta-catenin, gamma-catenin and cyclin D(1) in patients with esophageal squamous cell carcinoma (ESCC), and analyze their interrelationship with clinicopathological variables and their effec 15484291 Human
gamma-catenin tumor Expression of gamma-catenin was inversely correlated with the degree of tumor differentiation and lymph node metastasis (chi(2) = 4.183 and chi(2) = 5.035, respectively, P<0.05), whereas the expression of E-cadherin was correlated only with the degree of 15484291 Human
gamma-catenin lymph-node metastasis Expression of gamma-catenin was inversely correlated with the degree of tumor differentiation and lymph node metastasis (chi(2) = 4.183 and chi(2) = 5.035, respectively, P<0.05), whereas the expression of E-cadherin was correlated only with the degree of 15484291 Human
gamma-catenin tumor Reduced expression of E-cadherin and gamma-catenin was associated with poor differentiation of tumor, reduced expression of gamma-catenin was also associated with lymph node metastasis. 15484291 Human
gamma-catenin lymph-node metastasis Reduced expression of E-cadherin and gamma-catenin was associated with poor differentiation of tumor, reduced expression of gamma-catenin was also associated with lymph node metastasis. 15484291 Human
gamma-catenin esophageal carcinoma CONCLUSION: The reduced expression of E-cadherin and gamma-catenin, but not alpha-catenin, beta-catenin and cyclin D1, implies more aggressive malignant behaviors of esophageal carcinoma cells and predicts the poor prognosis of patients. 15484291 Human
gamma-catenin tumors Positivity for E-cadherin and alpha-, beta-, and gamma-catenin was significantly decreased in stage III and IV tumors compared with stage I and II tumors, suggesting that expression of the cadherin-catenin complex is reduced with the advancing stages of a 15619205 Human
gamma-catenin tumor Positivity for E-cadherin and alpha-, beta-, and gamma-catenin was significantly decreased in stage III and IV tumors compared with stage I and II tumors, suggesting that expression of the cadherin-catenin complex is reduced with the advancing stages of a 15619205 Human
gamma-catenin fibrous meningiomas The tumor cells constituting whorls and glandular structures of secretory type showed a strong immunoreactivity. gamma-Catenin expression tended to be weak and infrequent in fibrous meningiomas, while other types exhibited diffuse stainings. 15660696 Human
gamma-catenin meningiomas Quantitatively, there were no correlations between the histological variants, Ki-67 indexes, or grades of meningiomas and the immunoreactive scores except for gamma-catenin scores of fibrous meningiomas. 15660696 Human
gamma-catenin fibrous meningiomas Quantitatively, there were no correlations between the histological variants, Ki-67 indexes, or grades of meningiomas and the immunoreactive scores except for gamma-catenin scores of fibrous meningiomas. 15660696 Human
gamma-catenin renal-cell carcinoma Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. 15701841 Human
gamma-catenin tumor PURPOSE: Gamma-catenin is a cell adhesion protein, and its functional loss is associated with tumor invasion and metastasis. 15701841 Human
gamma-catenin metastasis PURPOSE: Gamma-catenin is a cell adhesion protein, and its functional loss is associated with tumor invasion and metastasis. 15701841 Human
gamma-catenin renal cell carcinoma (rcc) We hypothesize that (1) promoter CpG methylation regulates the expression and function of the gamma-catenin gene in renal cell carcinoma (RCC) and (2) methylation of the gamma-catenin gene is associated with poor prognosis of RCC. 15701841 Human
gamma-catenin renal cancer RESULTS: The demethylating agent (5-aza-2'-deoxycytidine) increased levels of mRNA transcript of the gamma-catenin gene in three renal cancer cell lines. 15701841 Human
gamma-catenin human pancreatic carcinoma Analysis of E-, N-Cadherin, alpha-, beta-, and gamma-Catenin Expression in Human Pancreatic Carcinoma Cell Lines. 15714139 Human
gamma-catenin human prostate cancer Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer. 15781623 Human
gamma-catenin prostate cancer We hypothesized that impaired regulation of gamma-catenin through genetic and epigenetic pathways is associated with the pathogenesis of prostate cancer. 15781623 Human
gamma-catenin prostate cancer To test this hypothesis, cytosine-phosphate-guanine methylation, loss of heterozygosity (LOH), and mutation status of the gamma-catenin gene were analyzed in cultured prostate cancer cell lines, 180 localized prostate cancers, 69 benign prostatic hyperpla 15781623 Human
gamma-catenin hormone refractory prostate cancers (hrpc) To test this hypothesis, cytosine-phosphate-guanine methylation, loss of heterozygosity (LOH), and mutation status of the gamma-catenin gene were analyzed in cultured prostate cancer cell lines, 180 localized prostate cancers, 69 benign prostatic hyperpla 15781623 Human
gamma-catenin benign prostatic hyperplasias To test this hypothesis, cytosine-phosphate-guanine methylation, loss of heterozygosity (LOH), and mutation status of the gamma-catenin gene were analyzed in cultured prostate cancer cell lines, 180 localized prostate cancers, 69 benign prostatic hyperpla 15781623 Human
gamma-catenin localized prostate cancers To test this hypothesis, cytosine-phosphate-guanine methylation, loss of heterozygosity (LOH), and mutation status of the gamma-catenin gene were analyzed in cultured prostate cancer cell lines, 180 localized prostate cancers, 69 benign prostatic hyperpla 15781623 Human
gamma-catenin prostate cancer In prostate cancer cell lines (DuPro, LNCaP, ND-1, and PC3), gamma-catenin mRNA transcripts were increased after 5-aza-2'-deoxycytidine treatment. 15781623 Human
gamma-catenin benign prostatic hyperplasia In localized prostate cancer, gamma-catenin expression was lower but prevalence of gamma-catenin methylation was higher compared with benign prostatic hyperplasia. 15781623 Human
gamma-catenin localized prostate cancer In localized prostate cancer, gamma-catenin expression was lower but prevalence of gamma-catenin methylation was higher compared with benign prostatic hyperplasia. 15781623 Human
gamma-catenin localized prostate cancers Among localized prostate cancers with positive gamma-catenin methylation, the presence of LOH at chromosome 17q21 was closely related to down-regulation of gamma-catenin mRNA expression. 15781623 Human
gamma-catenin localized prostate cancers The gamma-catenin mutations were not found in localized prostate cancers, whereas six mutations were found in five HRPCs within or close to the GSK-3beta consensus motif phosphorylation site, among which four HRPCs showed strong nuclear gamma-catenin accu 15781623 Human
gamma-catenin prostate cancer Therefore, although epigenetic gamma-catenin methylation is an early event in the development of prostate cancer, simultaneous events of epigenetic cytosine-phosphate-guanine methylation and genetic LOH may be responsible for functional loss of gamma-cate 15781623 Human
gamma-catenin human prostate cancer This is the first report to characterize the epigenetic and genetic regulation of gamma-catenin in human prostate cancer. 15781623 Human
gamma-catenin primary tumor Umbilical metastasis (Sister Joseph's nodule) as a first sign of a disseminated ovarian carcinoma: comparative immunohistochemical analysis of primary tumor and its metastases. 15823129 Human
gamma-catenin ovarian carcinoma Umbilical metastasis (Sister Joseph's nodule) as a first sign of a disseminated ovarian carcinoma: comparative immunohistochemical analysis of primary tumor and its metastases. 15823129 Human
gamma-catenin metastasis Umbilical metastasis (Sister Joseph's nodule) as a first sign of a disseminated ovarian carcinoma: comparative immunohistochemical analysis of primary tumor and its metastases. 15823129 Human
gamma-catenin metastases Umbilical metastasis (Sister Joseph's nodule) as a first sign of a disseminated ovarian carcinoma: comparative immunohistochemical analysis of primary tumor and its metastases. 15823129 Human
gamma-catenin tumor All specimens were positive for cytokeratin 7, CA 125, E-cadherin, alpha-, beta-, and gamma-catenin, as well as for MSH2. 15823129 Human
gamma-catenin metastasis All specimens were positive for cytokeratin 7, CA 125, E-cadherin, alpha-, beta-, and gamma-catenin, as well as for MSH2. 15823129 Human
gamma-catenin malignant tumors All specimens were positive for cytokeratin 7, CA 125, E-cadherin, alpha-, beta-, and gamma-catenin, as well as for MSH2. 15823129 Human
gamma-catenin epithelial ovarian tumours This study analysed the biological relevance of E-cadherin, alpha-catenin, beta-catenin and gamma-catenin immunoexpression pattern (reduced vs. preserved phenotype) in epithelial ovarian tumours. 15785075 Human
gamma-catenin colorectal cancer AIM: To examine the expression of E-cadherin, beta-catenin, gamma-catenin, VEGF, and p53 in 39 patients with hepatic metastasis from colorectal cancer immunohistochemically. 16149139 Human
gamma-catenin hepatic metastasis AIM: To examine the expression of E-cadherin, beta-catenin, gamma-catenin, VEGF, and p53 in 39 patients with hepatic metastasis from colorectal cancer immunohistochemically. 16149139 Human
gamma-catenin medulloblastomas Correlation of gamma-catenin expression with good prognosis in medulloblastomas. 16156230 Human
gamma-catenin medulloblastomas METHODS: Immunohistochemical and cytogenetic examinations of beta- and gamma-catenin, c-myc, N-myc, and cyclin D1 in 24 primary medulloblastomas were conducted, and their clinical relevance was evaluated. 16156230 Human
gamma-catenin invasive carcinomas Some investigations report the significance of E-CD associated proteins alpha-, beta-, gamma-catenin expression, as well as the usefulness of cytokeratins 5, 6, 8, 7 and thrombospondin in differentiating histological types of breast invasive carcinomas. 16170389 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.